Disease Introduction
Lung cancer is a malignant tumor with the highest incidence and mortality rate in my country. Early stages are often asymptomatic and are detected through low-dose spiral CT screening. After diagnosis, treatment is selected based on stage and gene type: for operable patients, minimally invasive surgical resection is performed combined with perioperative immunotherapy and targeted therapy; for inoperable or advanced-stage patients, targeted drugs, immunotherapy, and stereotactic radiotherapy are used, with the goal of prolonging survival and improving quality of life.
Cutting-edge high-precision diagnostic and treatment technologies
- Perioperative immunotherapy : KEYNOTE-671 confirmed that patients with resectable stage II to IIIB disease who received pembrolizumab combined with chemotherapy before and after surgery had a significantly better 24-month event-free survival rate than those who received chemotherapy alone.
- Postoperative adjuvant immunotherapy : IMpower010 shows that atezolizumab adjuvant therapy for stage II to IIIA patients has a 5-year disease-free survival rate of 53.2%, and has been included in the 2025 version of the perioperative quality control consensus.
- Third-generation targeted therapy approved : In January 2025, osimertinib was approved in China for EGFR-mutant stage III unresectable non-small cell lung cancer. The 2025 guidelines added efonapl as a first-line treatment for ALK fusion-positive lung cancer.
- Dual-target first-line treatment : In August 2025, ervantuzumab in combination with lanzatinib was approved in China for first-line treatment of advanced non-small cell lung cancer with classic EGFR mutations;
- Minimally invasive robot : After neoadjuvant immunochemotherapy, both robot-assisted and single-port VATS surgery are safe and feasible, and robot-assisted surgery results in a shorter postoperative ICU stay.
